Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate UroGen Pharma Ltd. before investing.

In this article, we go over a few key elements for understanding UroGen Pharma Ltd.’s stock price such as:

• UroGen Pharma Ltd.’s current stock price and volume
• Why UroGen Pharma Ltd.’s stock price changed recently
• Upgrades and downgrades for URGN from analysts
• URGN’s stock price momentum as measured by its relative strength

About UroGen Pharma Ltd. (URGN)

Before we jump into UroGen Pharma Ltd.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Want to learn more about UroGen Pharma Ltd.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about UroGen Pharma Ltd..

UroGen Pharma Ltd.’s Stock Price as of Market Close

As of June 12, 2026, 4:00 PM, CST, UroGen Pharma Ltd.’s stock price was $29.720.

UroGen Pharma Ltd. is up 0.75% from its previous closing price of $29.500.

During the last market session, UroGen Pharma Ltd.’s stock traded between $29.320 and $31.290. Currently, there are approximately 50.18 million shares outstanding for UroGen Pharma Ltd..

UroGen Pharma Ltd.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

UroGen Pharma Ltd. Stock Price History

UroGen Pharma Ltd.’s (URGN) price is currently up 5.65% so far this month.

During the month of June, UroGen Pharma Ltd.’s stock price has reached a high of $31.290 and a low of $26.000.

Over the last year, UroGen Pharma Ltd. has hit prices as high as $32.370 and as low as $11.510. Year to date, UroGen Pharma Ltd.’s stock is up 26.9%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused UroGen Pharma Ltd. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 12, 2026, there were 2 analysts who downgraded UroGen Pharma Ltd.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate UroGen Pharma Ltd.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on UroGen Pharma Ltd.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about UroGen Pharma Ltd. (URGN) by visiting AAII Stock Evaluator.

Relative Price Strength of UroGen Pharma Ltd.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 12, 2026, UroGen Pharma Ltd. has a weighted four-quarter relative price strength of 28.34%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how UroGen Pharma Ltd. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

UroGen Pharma Ltd. Stock Price: Bottom Line

As of June 12, 2026, UroGen Pharma Ltd.’s stock price is $29.720, which is up 0.75% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like UroGen Pharma Ltd. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.